Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial

BMC Nephrology

Volumn 13, Issue 1, 2012, Pages

  Bleskestad, Inger H ^a   Bergrem, Harald ^a   Hartmann, Anders ^b   Godang, Kristin ^b   Gøransson, Lasse G ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Active vitamin D; Chronic kidney disease; FGF23; Fibroblast growth factor 23; Parathyroid hormone; Phosphate binder; PTH; Sevelamer carbonate

Indexed keywords

25 HYDROXYVITAMIN D; ALFACALCIDOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FEBUXOSTAT; FIBROBLAST GROWTH FACTOR 23; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; PARATHYROID HORMONE; SEVELAMER CARBONATE; SPIRONOLACTONE; XANTHINE OXIDASE INHIBITOR; BIOLOGICAL MARKER; CHELATING AGENT; FIBROBLAST GROWTH FACTOR; POLYAMINE; SEVELAMER; VITAMIN; VITAMIN D;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; CROSSOVER PROCEDURE; DISEASE SEVERITY; DIURETIC THERAPY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MALE; PARATHYROID HORMONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; VITAMIN BLOOD LEVEL; BLOOD; CHRONIC KIDNEY FAILURE; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; CHELATING AGENTS; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; PARATHYROID HORMONE; POLYAMINES; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; VITAMIN D; VITAMINS;

EID: 84862768273     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-13-49     Document Type: Article

References (31)

1. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, et al. Am J Kidney Dis 2008 52 519 530 10.1053/j.ajkd.2008.03.020 18514987
2. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009 76 Suppl 103 1 S130
3. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Tentori F, Albert JM, Young EW, Blayney MJ, Robinson BM, Pisoni RL, Akiba T, Greenwood RN, Kimata N, Levin NW, et al. Nephrol Dial Transplant 2009 24 963 972 19028748
4. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, Vanderschueren D, Vanrenterghem Y, Clin J Am Soc Nephrol 2010 5 1268 1276 10.2215/CJN.08241109 20448073
5. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M, J Am Soc Nephrol 2005 16 2205 2215 10.1681/ASN.2005010052 15917335 (Pubitemid 41716454)
6. Overview of the FGF23-Klotho axis. Kuro-o M, Pediatr Nephrol 2010 25 583 590 10.1007/s00467-009-1260-4 19626341
7. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K, Tominaga Y, Otsuki N, Nibu K, Nakagawa K, et al. Kidney Int 2010 77 232 238 10.1038/ki.2009.414 19890272
8. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M, N Engl J Med 2008 359 584 592 10.1056/NEJMoa0706130 18687639
9. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu C-Y, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M, JAMA 2011 15 2432 2439
10. High phosphate content beverages in dialysis patients: relevance for hyperphosphatemia and cardiovascular risk. Savica V, Calo LA, Monardo P, Caldarera R, Cavaleri A, Santoro D, Muraca U, Mallamace A, Bellinghieri G, Nutr Metab Cardiovasc Dis 2008 18 39 e40 10.1016/j.numecd.2008.03.003 18571909
11. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, Ann Intern Med 1999 130 461 470 10075613 (Pubitemid 29135798)
12. Clinical trials. Altman DG, Practical Statistics for Medical Research Chapman and Hall/CRC, London 1999 467 471
13. The AB/BA design with normal data. Senn S, Cross-over Trials in Clinical Research John Wiley and Sons Ltd, Chichester, England 2 2002 42 47
14. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nishi H, Nii-Kono T, Nakanishi S, Yamazaki Y, Yamashita T, Fukumoto S, Ikeda K, Fujimori A, Fukagawa M, Nephron Clin Pract 2005 101 94 c99 10.1159/000086347 15956805 (Pubitemid 41208897)
15. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. Isakova T, Gutierrez O, Shah A, Castaldo L, Holmes J, Lee H, Wolf M, J Am Soc Nephrol 2008 19 615 623 10.1681/ASN.2007060673 18216315 (Pubitemid 351355405)
16. Sample size calculations. The little handbook of statistical practice. Dallal GE, 2008 http://www.lib.westfield.ma.edu/webmls.htm
17. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S, J Clin Endocrinol Metab 2002 87 4957 4960 10.1210/jc.2002-021105 12414858 (Pubitemid 35316332)
18. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. Ferrari SL, Bonjour JP, Rizzoli R, J Clin Endocrinol Metab 2005 90 1519 1524 15613425 (Pubitemid 40464013)
19. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS, J Bone Miner Res 2006 21 1187 1196 10.1359/jbmr.060507 16869716 (Pubitemid 44128331)
20. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. Antoniucci DM, Yamashita T, Portale AA, J Clin Endocrinol Metab 2006 91 3144 3149 10.1210/jc.2006-0021 16735491 (Pubitemid 44271770)
21. Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Vervloet MG, van Ittersum FJ, Buttler RM, Heijboer AC, Blankenstein MA, ter Wee PM, Clin J Am Soc Nephrol 2011 6 383 389 10.2215/CJN.04730510 21030580
22. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Isakova T, Gutierrez OM, Smith K, Epstein M, Keating LK, Juppner H, Wolf M, Nephrol Dial Transplant 2011 26 584 591 10.1093/ndt/gfq419 20631407
23. Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, Martinez-Calero A, Navas V, Rodriguez M, Ortiz A, Nephrol Dial Transplant 2011 26 2567 2571 10.1093/ndt/gfr144 21436379
24. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moyses RM, Clin J Am Soc Nephrol 2010 5 286 291 10.2215/CJN.05420709 19965540
25. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Dusso AS, Tokumoto M, Kidney Int 2011 79 715 729 10.1038/ki.2010.543 21270766
26. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T, J Bone Miner Res 2004 19 429 435 15040831 (Pubitemid 38787398)
27. Novel mechanisms in the regulation of phosphorus homeostasis. Berndt T, Kumar R, Physiology (Bethesda) 2009 24 17 25 10.1152/physiol.00034.2008
28. The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder. Slatopolsky E, Kidney Int 2011 79 3 S8
29. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Berndt T, Thomas LF, Craig TA, Sommer S, Li X, Bergstralh EJ, Kumar R, Proc Natl Acad Sci U S A 2007 104 11085 11090 10.1073/pnas.0704446104 17566100 (Pubitemid 47175230)
30. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, Yamashita T, Fujita T, J Bone Miner Metab 2007 25 419 422 10.1007/s00774-007- 0779-3 17968495 (Pubitemid 350043699)
31. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto H, Takeda E, Kidney Int 2006 70 2141 2147 17063170 (Pubitemid 44871378)